Scarica l'app Stockscreener
173.82
0.47%
0.81
Pre-mercato:
173.47
-0.35
-0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BDX Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$173.01
Aprire:
$173.47
Volume 24 ore:
2.68M
Relative Volume:
0.99
Capitalizzazione di mercato:
$49.82B
Reddito:
$20.87B
Utile/perdita netta:
$1.50B
Rapporto P/E:
33.17
EPS:
5.24
Flusso di cassa netto:
$2.59B
1 W Prestazione:
+0.88%
1M Prestazione:
-15.80%
6M Prestazione:
-21.67%
1 anno Prestazione:
-22.77%
Intervallo 1D:
$171.90
$174.47
Intervallo di 1 settimana:
$169.60
$176.43
Portata 52W:
$163.33
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Nome
Becton Dickinson Co
Settore
Industria
Telefono
(201) 847-6800
Indirizzo
ONE BECTON DR, FRANKLIN LAKES
Confronta BDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
173.82 | 49.39B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
555.75 | 194.50B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
86.35 | 42.61B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
245.12 | 36.00B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
79.96 | 15.86B | 3.93B | 415.40M | 384.70M | 2.06 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-02 | Downgrade | Goldman | Buy → Neutral |
| 2025-05-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-05-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-12-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2022-07-11 | Downgrade | Citigroup | Neutral → Sell |
| 2022-06-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Ripresa | Raymond James | Mkt Perform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2021-12-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Iniziato | Barclays | Equal Weight |
| 2020-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Ripresa | Goldman | Buy |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-07 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-02-07 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-01-08 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Iniziato | Deutsche Bank | Buy |
| 2018-10-16 | Iniziato | Barclays | Equal Weight |
| 2018-06-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-01-19 | Ripresa | BofA/Merrill | Buy |
| 2018-01-05 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-01-05 | Iniziato | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2017-12-29 | Reiterato | Deutsche Bank | Buy |
Mostra tutto
Becton Dickinson Co Borsa (BDX) Ultime notizie
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - BD Newsroom
Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com
Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance
AC Health, Becton Dickinson team up to elevate healthcare standards across Asia - Bilyonaryo Business News
Becton Dickinson stock rating cut by Citi to Neutral, target to $185 - Investing.com India
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut b - GuruFocus
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut by Citigroup | BDX Stock News - GuruFocus
6 Analysts Have This To Say About Becton Dickinson - Benzinga
Becton Dickinson (BDX) Downgraded by Citi to Neutral | BDX Stock News - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challen - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challenges | BDX Stock News - GuruFocus
Citigroup Downgrades Becton Dickinson and Co. to Neutral From Buy, Adjusts PT to $185 From $217 - marketscreener.com
BD aims to secure slice of medical technology market - BusinessMirror
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' - BD Newsroom
FBI probes North Canaan suspicious package that contaminated hundreds: What we know and don't know - CT Insider
Becton, Dickinson and Company Stock: Analyst Estimates & Ratings - inkl
Becton, Dickinson And Company Stock: Analyst Estimates & Ratings - Barchart.com
Becton, Dickinson and Company (BDX): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Argus Adjusts Price Target on Becton Dickinson and Co. to $220 From $270, Maintains Buy Rating - marketscreener.com
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Becton Dickinson Sues Baxter Over Infusion Pump Patents - Law360
Becton Dickinson at Bank of America Conference: Navigating Challenges and Opportunities - Investing.com Nigeria
Transcript : Becton, Dickinson and Company Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Judge declares mistrial in punitive damages phase in Walker v. BD - The Covington News
Becton Dickinson Says Baxter Infringes Infusion-Pump Patents (1) - Bloomberg Law News
Sterile Lancets Market Set to Grow | Key Players: Roche, Becton Dickinson, Medtronic - openPR.com
Becton Dickinson (BDX) Unveils Advanced Cell Analyzer - GuruFocus
BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies - marketscreener.com
First Eagle Investment's Strategic Moves: Spotlight on Becton Dickinson & Co - Yahoo Finance
Becton Dickinson & Co (BDX) Shares Up 3.73% on May 12 - GuruFocus
Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts - MSN
The Strong Earnings Posted By Becton Dickinson (NYSE:BDX) Are A Good Indication Of The Strength Of The Business - Yahoo
Morgan Stanley Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $196.00 - Defense World
SEC Form 4 filed by Director Byington Carrie L - Quantisnow
Becton, Dickinson downgraded at more firms following Q2 results - MSN
Becton Dickinson downgraded to Neutral from Buy at Goldman Sachs - MSN
Jim Cramer on Becton, Dickinson and Company (BDX): “A Shocking Miss for This Once-Reliable Med Tech Giant” - Insider Monkey
Mistrial declared after jury awards $50M in landmark toxic gas case - AJC.com
Becton Dickinson (NYSE:BDX) Sees 18% Price Dip Over Last Week - Yahoo Finance
Becton Dickinson (BDX) Price Target Lowered by Morgan Stanley | BDX Stock News - GuruFocus
Investors Can Still File Late Claims for Becton, Dickinson & Co $85M Settlement Payouts - TradingView
Morgan Stanley Adjusts Price Target on Becton, Dickinson and Company to $196 From $280, Maintains Overweight Rating - marketscreener.com
Covington resident wins $20 million in case against Becton Dickinson - The Covington News
Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales - MSN
Becton Dickinson Co Azioni (BDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):